Quantcast

Alan James Group Launches Enhanced Websites for Existing Nutritional Supplement Product Line

August 21, 2008

BOCA RATON, Fla., Aug. 21 /PRNewswire-FirstCall/ — Alan James Group (AJG), a wholly owned subsidiary of Interleukin Genetics, Inc. , announced today that it has launched several new websites for its line of branded nutritional supplements, including Ginsana(R), Ginkoba(R), Venastat(R), Optiform SAM-e(R), Cransana(R) and Ginsana Gold Multiplex(R). AJG markets items in multiple categories in the Food, Drug and Mass (FD&M) channels, including Energy, Memory, Leg Vein Health and Heart Health. AJG also distributes Kyolic(R) in the FD&M channels under an agreement with Wakunaga of America Co. Ltd.

“Our products help enhance energy and memory, promote leg circulation, support cholesterol, joint and urinary tract health, and improve general wellness,” said Woody Kassin, General Manager of AJG. “We believe our products can help individuals to lead healthier and more fulfilling lives.

“The product-specific websites provide scientific research regarding how AJG branded nutritional supplements may help promote a healthy lifestyle, as well as education on proper usage. In addition, each website provides product information including ingredient descriptions, recommended daily dosage, as well as where the products can be purchased and the money back quality guarantee. The new websites are: http://www.ginsana.com/, http://www.ginkoba.com/, http://www.venastat.com/, http://www.optiformsame.com/, http://www.cransana.com/ and http://www.kyolic.com/.

“We are pleased to offer consumers high quality nutritional products,” said Brian Baer, Vice President of Sales and Marketing at AJG. “The new websites showcase a unique and fresh design to our formulas and offer consumers significantly more information about the benefits of our products. Our products can be purchased on-line and in over 30,000 stores nationwide, including all major retail chains.”

About Alan James Group

Alan James Group, a wholly owned subsidiary of Interleukin Genetics, Inc., is a healthcare-focused consumer products company targeting the growing market for self-medication and preventive healthcare products. Alan James Group currently markets and sells a line of branded nutritional supplements, including Ginsana(R), Ginkoba(R), Venastat(R), Optiform SAM-e(R), Cransana(R), and Ginsana Gold Multiplex(R), most of which have been in the market for more than 10 years, to major discount retailers, drugstores, grocery stores and warehouse clubs in the United States. For more information about Alan James, please visit http://www.alanjamesgroup.com/.

About Interleukin Genetics

Interleukin Genetics, Inc. , is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginsana(R), Ginkoba(R) and Venastat(R), which are sold at the nation’s largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit http://www.ilgenetics.com/.

Certain statements contained herein are “forward-looking” statements including statements regarding the Company’s ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, the ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and the ability to make progress in advancing the Company’s core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of the Company’s products, the risk of technology and product obsolescence, delays in product development, the performance of commercial partners, the availability of adequate capital, the actions of competitors and other competitive risks, and those risks and uncertainties described in the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings furnished to the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.

Alan James Group

CONTACT: Media: Catherine Cloft of LaVoie Group for the Alan JamesGroup, +1-978-745-4200, ext. 107, ccloft@lavoiegroup.com; or InvestorRelations: Melanie Friedman, Stern Investor Relations, +1-212-362-1200,melanie@sternir.com

Web site: http://www.alanjamesgroup.com/http://www.ilgenetics.com/http://www.ginsana.com/http://www.ginkoba.com/http://www.venastat.com/http://www.optiformsame.com/http://www.cransana.com/http://www.kyolic.com/




comments powered by Disqus